Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost. The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mortality and prolonged hospitalization in cancer patients with FN.

[1]  H. Einsele,et al.  Central venous catheter-related infections in hematology and oncology , 2008, Annals of Hematology.

[2]  G. Lyman,et al.  Length of stay and mortality associated with febrile neutropenia among children with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Lyman.  Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  V. Caggiano,et al.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy , 2005, Cancer.

[5]  J. Friedberg,et al.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Gary H Lyman,et al.  Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  R. Wenzel,et al.  Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[9]  G. Lyman,et al.  Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy , 2003, Leukemia & lymphoma.

[10]  É. Azoulay,et al.  Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients , 2002, Intensive Care Medicine.

[11]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[12]  M. Hussain,et al.  Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. , 2001, The Journal of infection.

[13]  A. Tres,et al.  Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. , 2001, Journal of the National Cancer Institute.

[14]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Salar,et al.  Prognostic Factors Influencing Mortality in Cancer Patients with Neutropenia and Bacteremia , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  G. Lyman,et al.  The economics of febrile neutropenia: implications for the use of colony-stimulating factors. , 1998, European journal of cancer.

[17]  A. Ravaud,et al.  Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Alcaide,et al.  Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. , 1998, Archives of internal medicine.

[19]  L. Elting,et al.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  E. González-Barca,et al.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  A. Neugut,et al.  Diagnostic and management issues in gallbladder carcinoma. , 1995, Oncology.

[22]  Max Wolf,et al.  Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[23]  G. Lyman,et al.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. , 1993, Journal of the National Cancer Institute.

[24]  R. Finberg,et al.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Mayer,et al.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. , 1988, Archives of internal medicine.

[26]  F. Rossini.  Prognosis of infections in elderly patients with haematological diseases , 2005, Supportive Care in Cancer.

[27]  G. Lyman,et al.  Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2003, The Cochrane database of systematic reviews.

[28]  ICD-9-CM Official Guidelines for Coding and Reporting , 2002 .

[29]  E. Anaissie,et al.  Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. , 1996, The American journal of medicine.

[30]  M. Brown,et al.  The costs of cancer care in the United States: implications for action. , 1995, Oncology.